Probable Interaction Between Warfarin and Inhaled and Oral Administration of Cannabis

被引:23
作者
Hsu, Amy [1 ]
Painter, Nathan A. [1 ]
机构
[1] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, 9500 Gilman Dr,MC 0657, La Jolla, CA 92093 USA
关键词
ambulatory care; anticoagulation; medication safety; cannabis; DRUG-INTERACTION;
D O I
10.1177/0897190019854958
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To report a probable interaction between warfarin and edible cannabis that resulted in an elevated international normalized ratio (INR) without bleeding complications. Case Summary: A 35-year-old Middle Eastern male on warfarin long term with an INR goal of 2.5 (accepted range: 2.0-3.0). The patient has generally been stable on warfarin 10 mg daily from 2010 to 2018, until INR suddenly increased to 7.2 following 1 month of edible cannabis ingestion and cannabis smoking. Patient denied any signs and symptoms of bleeding. No other reasonable causes of the elevation in INR were apparent. The patient was advised to hold 2 doses of warfarin and discontinue cannabis use. The INR dropped below 4 upon discontinuation of cannabis with dose adjustments to warfarin. Discussion: The elevation in INR can be explained by the inhibition of CYP2C9 by cannabis use causing decreased metabolism of warfarin. The interaction between warfarin and cannabis was determined to be probable using the Horn Drug Interaction Probability Scale. Conclusions: There are no previous reports of interactions between edible cannabis and warfarin, with very few case reports describing the interaction with other forms of cannabis. Close monitoring of INR in patients with concomitant cannabis is recommended for proper warfarin management.
引用
收藏
页码:915 / 918
页数:4
相关论文
共 15 条
[1]   Cannabis, a complex plant: different compounds and different effects on individuals [J].
Atakan, Zerrin .
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2012, 2 (06) :241-254
[2]   CONTROLLED CLINICAL-TRIAL OF CANNABIDIOL IN HUNTINGTONS-DISEASE [J].
CONSROE, P ;
LAGUNA, J ;
ALLENDER, J ;
SNIDER, S ;
STERN, L ;
SANDYK, R ;
KENNEDY, K ;
SCHRAM, K .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1991, 40 (03) :701-708
[3]   Interaction between warfarin and cannabis [J].
Damkier, Per ;
Lassen, Dorte ;
Christensen, Mette Marie Hougaard ;
Madsen, Kenneth Gronkjaer ;
Hellfritzsch, Maja ;
Pottegard, Anton .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 124 (01) :28-31
[4]   Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy [J].
Geffrey, Alexandra L. ;
Pollack, Sarah F. ;
Bruno, Patricia L. ;
Thiele, Elizabeth A. .
EPILEPSIA, 2015, 56 (08) :1246-1251
[5]   Proposal for a new tool to evaluate drug interaction cases [J].
Horn, John R. ;
Hansten, Philip D. ;
Chan, Lingtak-Neander .
ANNALS OF PHARMACOTHERAPY, 2007, 41 (04) :674-680
[6]   Human P450 metabolism of warfarin [J].
Kaminsky, LS ;
Zhang, ZY .
PHARMACOLOGY & THERAPEUTICS, 1997, 73 (01) :67-74
[7]   A Brief Background on Cannabis: From Plant to Medical Indications [J].
Klumpers, Linda E. ;
Thacker, David L. .
JOURNAL OF AOAC INTERNATIONAL, 2019, 102 (02) :412-420
[8]   The pharmacokinetics and the pharmacodynamics of cannabinoids [J].
Lucas, Catherine J. ;
Galettis, Peter ;
Schneider, Jennifer .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (11) :2477-2482
[9]  
McCarberg Bill H, 2007, Am J Ther, V14, P475, DOI 10.1097/MJT.0b013e3180a5e581
[10]  
National Conference of State Legislatures, 2018, STAT MED MAR LAWS